M alignant pleural mesothelioma (MPM) is a highly lethal tumor whose pathogenesis intimately correlates with occupational or environmental exposure to asbestos fibers. Despite a generalized ban on asbestos usage in most countries, the incidence and mortality from MPM is expected to steadily increase in the next few years as a result of the prolonged interval between asbestos exposure and the clinical presentation of the disease. 1 Because of the aggressive biologic behavior of MPM, patient selection is crucial to improve clinical outcomes. Eligibility to radical surgery is limited to patients with early stage disease and intact cardiorespiratory function; however, pleural decortication or extrapleural pneumonectomy has demonstrated a limited survival benefit when used alone, 2 and multimodal treatments integrating radiation or systemic therapy have gained importance in MPM. 3 Platinum-based chemotherapy in combination with pemetrexed yields the highest tumor response rates, and its beneficial impact on patient survival and quality of life has made it the systemic regimen of choice for MPM in both the neoadjuvant and the palliative setting. 4 However, the delicate context of a short-life expectancy in conjunction with potential side effects and only modest survival benefit offered by the currently available treatments belies the importance of a case-by-case risk-benefit assessment before any active treatment is administered. 5 The identification of prognostic determinants is, therefore, needed to stratify patients into distinct risk categories and optimize the provision of the currently available treatments, both in the radical and palliative setting. 6 A number of clinicopathologic features have been proven to predict prognosis in MPM. Sarcomatoid differentiation, elevated platelet and white blood cell (WBC) count, and more advanced performance status (PS) have been recognized to reflect a more aggressive disease course. 7, 8 In an attempt to standardize the prognostic assessment in MPM, some of these clinically significant variables have been incorporated into coherent prognostic models. The European Organization for the Research and Treatment of Cancer Prognostic Score (EPS) has been devised to subcategorize patients into favorable or adverse prognostic groups based on patient's age and PS, presence and subtype of histologic diagnosis, and WBC count at presentation. 9 The Cancer and Leukemia Group B score is a more complex system that incorporates the presence of nonepithelial histology, weight loss or chest pain, high platelet and WBC count, low hemoglobin, high serum lactate dehydrogenase, advanced age, and PS. 10 The reliability of these prognostic models has been strengthened by a process of validation in independent patient cohorts. 11 However, despite having generated some scientific interest in the past, these scores are rarely used outside the specific context of clinical trials.
The presence of a systemic inflammatory reaction in patients with a diagnosis of cancer is deemed to reflect the release of cytokines by the tumor itself or a host response toward the tumor. Besides being involved in the pathogenesis of cancer-related cachexia and nutritional decline, systemic inflammation has been shown to predict clinically meaningful outcomes such as overall and recurrence-free survival as well as response to systemic treatment. 12 Several inflammationbased prognostic scoring systems have been devised to quantify systemic inflammation from a clinical standpoint. These include the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), both of which reflect full blood count derangements induced by the acute phase reaction, 13 while the modified Glasgow Prognostic Score (mGPS) uses raised circulating C-reactive protein (CRP) and hypoalbuminemia. 14 Convincing evidence supports the role of tumor-produced proinflammatory cytokines in the progression of MPM. 15 However, despite having been extensively studied in several solid tumor types, the prognostic impact of systemic inflammation has been relatively unaddressed in MPM. Recently, the independent prognostic value of the NLR, an inflammatory-related biomarker, was qualified in a single-center study of patients with a diagnosis of MPM undergoing systemic treatment in the context of phase II/III clinical trials. 16 Interestingly, NLR status could efficiently subdivide patients into two distinct categories with a survival difference of more than 10 months observed, whereas the EPS did not retain independent prognostic value, casting doubt on its predictive ability. Although Kao et al. qualified the NLR as a predictor of overall survival (OS) in MPM, statistical validation of its prognostic power was not carried out, a crucial step before this biomarker can enter the routine clinical arena. In addition, the single-center nature of this study in conjunction with a patient population composed mostly of clinical trial patients (i.e., with generally better PS) may limit the generalizability of this observation. 17 Moreover, currently, it is unknown which inflammatory-related score best predicts survival, as a comparative assessment of their predictive ability has never been performed in patients suffering from MPM. The aim of this study is, therefore, to assess the prognostic role of NLR, PLR, and mGPS in MPM. Furthermore, in a subset of patients, we sought to determine whether a relationship existed between systemic inflammation and tissue expression of proliferation and angiogenesis biomarkers.
PATIENTS AND METHODS

Patient Population
Patients with a histologically proven diagnosis of MPM presenting to the Imperial College NHS Healthcare Trust between 1993 and 2011 were included in the study. We identified 202 patients, from which cases with a positive history of inflammatory disease (n ϭ 3), second primary tumor (n ϭ 2), active infection (n ϭ 4), or insufficient follow-up data (n ϭ 22) were excluded, to give a total number of patients meeting the inclusion criteria of 171. Clinical variables such as demographic data and staging information were collected along with the complete blood picture, albumin, and CRP. Patients were staged according to International Mesothelioma Interest Group guidelines 18 where possible. Because of the known inaccuracy of radiologic tumor staging, classes I-II and III-IV were grouped together. 19 The mGPS was calculated as described in previous studies. 20 Briefly, patients with both a normal albumin (Ͼ35 g/liter) and CRP (Ͻ10 mg/liter) were allocated a score of 0. Patients in whom only one of these abnormalities was present were allocated a score of 1, whereas those with both abnormal CRP and albumin were given a score of 2. The NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. NLR Ն 5 was considered elevated as described previously. 21 The same calculation was applied to derive the PLR, with 300 being the cutoff for positivity, in accordance with the previously published literature. 22 The following parameters were considered as potential prognostic factors: gender, PS (0 versus Ն1), histologic subtype (epithelioid versus nonepithelioid), EPS, International Mesothelioma Interest Group stage, baseline WBC and platelet count, CRP, albumin, and difference in hemoglobin relative to 160 g/liter in men and 140 g/liter in women. 23 The EPS was derived as described previously and categorizes patients into good versus poor prognostic groups according to male gender, probable or possible histologic diagnosis, sarcomatoid differentiation, PS Ն1, and WBC Ͼ8.3 ϫ 10 9 / liter. 24 OS was calculated from the time of the biopsy to that of death or last follow-up. All the laboratory parameters were collected before the biopsy. The cutoff values adopted to categorize laboratory values are reported in Table 1 and justified as to their prognostic value by previously published evidence. 16, 23, 24 Survival status was updated as of the August 2011. The study was approved by the Local Research Ethics Committee.
Immunohistochemistry
Twenty patients were selected at random from the database and stratified into two subgroups (n ϭ 10) according to their inflammatory score: group A were patients with both NLR Ͻ5 and mGPS 0 or 1 and group B consisted of patients with NLR Ն5 and mGPS of 2. The median survival of patients in group A was 25.9 months and group B was 3.6 months. After review of hematoxylin and eosin slides by a board certified senior pathologist with more than 10 years expertise in pulmonary pathology (F.M.), paraffin-embedded tissue samples from representative blocks were cut into 4-m-thick sections, deparaffinized in xylene and graded alcohols, and subsequently rehydrated. Immunostaining for Ki-67 (Leica Microsystems, Germany 1:800 dilution) and vascular endothelial growth factor (VEGF; Santa Cruz, CA, 1:750 dilution) was performed using the Bond Max Autostainer (Leica Microsystems, Germany) after appropriate antigen unmasking. 25 Appropriate positive controls were assessed simultaneously using human tonsil and breast carcinoma specimens as per manufacturer's instructions. To further validate the specificity of the reaction, omission of the primary antibody was carried out in parallel, which resulted in negative staining in all cases. VEGF immunopositivity was scored accounting to both the percentage of positive cells (ranging from 0 to 100) and the intensity of the signal, defined as weak (1), medium (2), or strong (3). Percentage of positive cells and intensity of staining were multiplied together giving rise to a composite immunohistochemical score ranging from 0 to 300, as described earlier. 26 The Ki-67 labeling index was expressed as the percentage of immunopositive nuclei from a minimum of 500 nuclei in at least five microscopic fields. All the immunohistochemical staining were independently examined by two observers (F.M. and D.J.P.) blinded to outcomes. Consensus was reached between the two scorers in any case of discordance.
Statistical Analysis
Pearson 2 test was used to assess for any associations between clinicopathologic variables. Differences in VEGF expression scores and proliferative index were assessed using the Mann-Whitney U test. Kaplan-Meier statistics and logrank test were used to study the impact of the different clinical factors associated with survival using univariate analysis. The independent prognostic value of each significant factor was subsequently explored on multivariate analysis using a stepwise backward Cox proportional hazard model. Variables with a p value greater than 0.10 were removed from the model. A p value of Ͻ0.05 was considered as being significant. Statistical analysis was performed using SPSS statistical package version 11.5 (SPSS Inc., Chicago, IL) and GraphPad PRISM (GraphPad Software, Inc., La Jolla, CA).
RESULTS
Patient Demographics
The baseline patient characteristics are shown in Table  1 . The majority was male (84%) and had a diagnosis of stage III/IV disease (47%). Seventy patients (41%) had received frontline systemic therapy. Seventy-two (42%) patients received best supportive care. Treatment data were not available for 46 (17%) patients. At the time of analysis, 138 (86%) patients had died, and the median OS was 9.7 months (95% confidence interval [CI] ϭ 8.1Ϫ11.4).
Although baseline bloods were available for all patients, albumin was only available for 158 patients and CRP for 148 patients. Full clinical staging was only available for 128 patients. EPS was available for 142 patients; 83 patients (59%) had good risk; and 59 patients (41%) were of poor risk. 
Inflammatory Markers and Baseline Characteristics
Sixty-two patients (36%) of patients had an NLR Ն5, which was significantly associated with baseline raised platelet counts. A PLR greater than 300 was seen in 60 patients (35%) and was associated with male gender and nonepithelioid subtype. The majority of patients had an abnormal mGPS (66%), which was associated with worse PS, high white cell count, high platelet count, and a greater than 10 g/liter difference in hemoglobin at baseline (Table 2) .
Prognostic Variables Associated with Survival
Univariate analysis variables that predict for poor OS included male gender (p ϭ 0.03), nonepithelioid histologic subtype (p ϭ 0.03), PS Ն 1 (p ϭ 0.007), high-risk EPS (p ϭ 0.003; Figure 1A ), baseline WBC count Ն8.3 ϫ Table 2 ). Multivariate analysis revealed mGPS (hazard ratio ϭ 2.6; 95% CI ϭ 1.6Ϫ4.2; p Ͻ 0.001) and NLR (hazard ratio ϭ 2.0; 95% CI ϭ 1.6Ϫ3.2; p ϭ 0.008) as independent predictors of OS.
OS rates at 1 year from diagnosis were 72, 35, and 17% in patients with an mGPS of 0, 1, and 2, respectively, whereas the 2-year survival rate was 29% for mGPS 0, 17% for mGPS 1, and 4% for mGPS 2 ( Figure 1B) . Similarly, the 1-year survival rate for patients with an NLR Ͻ 5 was 39% versus 26% for those with an NLR Ն 5, whereas the 2-year survival 
Association between Inflammatory Scores and Tumor Proliferation and Angiogenesis
Tissue specimens obtained from patients in group B had a significantly higher proliferative index compared with those in group A (median nuclear count 55.5 versus 8.5, p Ͻ 0.001; Figure 2A ). Likewise, a significantly increased VEGF immunopositivity was observed in group B compared with group A (median immunohistochemical score 225.0 versus 60.0, p Ͻ 0.001; Figure 2B ). Representative tissue sections for each group are shown in Figure 3 . The clinicopathologic features of the selected cases are summarized in Table 3 .
DISCUSSION
The ability to accurately predict prognostic information has been the focus of research in MPM over the past few years. Several models have been developed, each one including parameters reflecting respiratory symptoms, baseline pathologic factors, and tumor stage. Unfortunately, none of these clinical staging methods is considered ideal, and despite the increasing number of comparative studies published, there is no consensus as to the optimal staging system. As a sustained inflammatory response plays a key role in the pathogenesis of MPM, we compared the utility of three widely used inflammation-based prognostic scores in determining OS in a heterogeneous group of patients with MPM.
There is an increasing evidence in the literature supporting the association between inflammatory markers and the overall prognosis in a wide variety of cancers. 16, [27] [28] [29] Previous reports have shown that the NLR is a predictor of outcome in MPM; however, this has only been investigated in a single-center retrospective study solely of patients undergoing systemic treatment. 16 In our analysis, male gender, nonepithelioid histologic subtype, poor PS, low risk EPS, increased WBC count, and the inflammatory markers NLR, PLR, CRP, albumin, and mGPS Ն1 were shown to be predictive of worse OS on univariate analysis. However, only NLR and mGPS qualified as a true independent predictor of survival on multivariate analysis. mGPS was able to stratify patients groups with a survival differences of 8 months between mGPS 0 and 1 (18.7 versus 10.5), and 11 months between mGPS 0 and 2 (18.7 versus 7.3). The survival difference was smaller between patients with NLR Ն5 and NLR Ͻ5 (3 months). To our knowledge, this is the first study to independently validate the prognostic role of mGPS and NLR in a large cohort of patients presenting FIGURE 2. Distribution of the proliferative index (A) and vascular endothelial growth factor (VEGF) expression values (B) across the two studied groups (n ϭ 10 each). Differences in medians were tested using the Mann-Whitney U test. consecutively with a diagnosis of MPM. Furthermore, the baseline characteristics of our patient cohort were comparable with a previous phase III study in MPM in terms of baseline patient characteristics and median survival. 4 Therefore, although the cohort data were collected retrospectively, it is representative of patients with MPM presenting to an Oncology Department.
Interestingly, in our multivariable screening of prognostic indicators, two simple inflammation-based parameters, the mGPS and NLR, performed better than the EPS, whose clinical use in the prognostic assessment of MPM had initially been endorsed as a stratifying system to facilitate patient selection in clinical trials, 24 but more recently questioned in further published reports. 16 Our results are consistent with the study by Kao et al. who reported that an elevated NLR not only predicted OS, but in those patients where raised NLR normalized after one cycle of chemotherapy, outcome was better than those in whom NLR remained persistently elevated. 16 The main difference between the study by Kao et al. and this report pertains to the study population. Kao et al. only considered those patients receiving systemic treatment, whereas we considered consecutive patients presenting to clinic regardless of treatment status. In general, it is well recognized that patients with good PS tend to be offered systemic therapy both in a trial and clinical setting. 17 It is possible, therefore, that the study cohort in the article by Kao et al. may have had a better overall PS than those in our cohort, 42% of whom did not receive any treatment. This may account for the difference in OS observed between NLR groups in the two studies.
Given the pathologic role of chronic inflammation in the development of MPM, 30 our results that inflammatorybased biomarkers are predictive of survival are not surprising. Moreover, we showed that both NLR and mGPS correlate significantly with a number of adverse clinicopathologic parameters such as increased platelet counts and WBC, anemia, and more advanced PS, suggesting that both inflammatory scores are predictive of a more aggressive clinical behavior. To further reinforce this concept, we demonstrated that derangement of proinflammatory indices reflects an increase in both tumor cell proliferation and tissue expression of VEGF in a subgroup of primary mesothelioma samples (Figures 2 and 3) . Taken together, these data suggest that inflammatory scores can stratify patients into different clinical and biological categories, with diverse survival outcomes.
Indeed, the interplay between inflammation, angiogenesis, and cellular proliferation is a concept consolidated in MPM. Previous studies have shown that tumor-secreted proinflammatory cytokines correlate with clinical progression, 31, 32 promotion of angiogenesis, 33 and suppression of antitumor immune response. 34 A number of studies have considered the interplay between circulating proangiogenic factors, including VEGF, and clinical outcome, with no association reported. 16, 35 However, the reliability of circulating VEGF as a biomarker of angiogenesis is limited by artifacts such as direct release from activated platelets and has not been shown to be a reliable biomarker of angiogenesis. 36, 37 A number of studies have tried to elucidate the individual cytokines driving the inflammatory response associated with malignancy with inconclusive results. 16, 35 It is likely that not one cytokine is involved, but that there is a complex interplay of proinflammatory cytokines and growth factors that is reflected by the mGPS and NLR. Therefore, our data suggest that the mGPS and NLR may be more reliable and reproducible surrogates of neoangiogenesis and proliferation in MPM. Although provocative, these results require further validation.
On the basis of on our preliminary results, and of the previously observed predictive value of inflammatory markers, we speculate that the mGPS and NLR may not only be useful as a statistically validated tool to support patient selection in clinical trials but also as pharmacodynamic biomarkers in prospective studies evaluating novel experimental therapies in MPM. Although these implications may not be directly inferred by our retrospective study, the lack of predictive markers of response to systemic treatment, especially in the context antiangiogenic treatments, encourages further prospectively designed studies to further validate the surrogate relationship between inflammatory indices and tumor neoangiogenesis.
In conclusion, the choice between pursuing active anticancer therapy rather than palliation of symptoms can be challenging in MPM. Currently, treatment allocation in MPM is dependent on a number of subjective parameters such as PS. 38 Our analysis of prognostic variables in a cohort of patients with MPM validates the mGPS and NLR, but not the PLR, as independent predictors of OS. Interestingly, our results show that mGPS and NLR are superior to PS alone in predicting patient's survival. We also examined the EPS and a number of other known prognostic parameters, but these were not confirmed as independent prognostic factors on multivariate analysis. The retrospective nature of our study, and the significant amount of missing data from our cohort, needs to be taken into consideration when considering these findings. The time span of 18 years during which the study was conducted could represent a source of heterogeneity in our patient series as a result of the progressively improved diagnostic and therapeutic management of MPM, especially after the introduction of more effective agents such as pemetrexed. However, recent evidence suggests that the OS rates and the distribution of prognostic factors are not different in patients treated before or after the introduction of pemetrexed. 39 Moreover, we were unable to compare the utility of the Cancer and Leukemia Group B prognostic score because of incomplete clinical information. This would be an important correlation in any future studies considering prognostic variables in MPM. The expected contribution of a prognostic marker is to facilitate and make the clinical assessment of the patient's prognosis more objective both in routine practice and in clinical research. The desirable features of a stratifying biomarker include reliability, reproducibility, inexpensiveness, and simplicity of use. The inflammatory-related markers, NLR and mGPS, are simple, validated, and universally available biomarkers. Our results are provocative in suggesting that the assessment of simple inflammatory tests could be incorporated into routine clinical practice and in clinical research to allow for accurate prognostication and identification of subgroups of patients in whom active treatments can be administered more safely or with better outcomes. Furthermore, prospectively conducted studies are warranted to validate the clinical applicability of these scores.
